- Home
- WOOF vs CDNA Comparison
WOOF vs CDNA Comparison
Compare WOOF & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | CDNA |
|---|---|---|
| Founded | 1965 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 1.0B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | WOOF | CDNA |
|---|---|---|
| Price | $3.63 | $17.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $3.90 | ★ $27.33 |
| AVG Volume (30 Days) | ★ 2.8M | 539.5K |
| Earning Date | 06-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.26 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $6,116,462,000.00 | $48,324,000.00 |
| Revenue This Year | $2.61 | $15.37 |
| Revenue Next Year | $1.63 | $11.23 |
| P/E Ratio | $81.51 | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $2.24 | $10.96 |
| 52 Week High | $4.19 | $21.49 |
Technical Indicators
Market Signals| Indicator | WOOF | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 78.30 | 37.34 |
| Support Level | $3.32 | $16.74 |
| Resistance Level | $3.70 | $17.09 |
| Average True Range (ATR) | 0.18 | 0.83 |
| MACD | 0.11 | -0.21 |
| Stochastic Oscillator | 88.31 | 23.77 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.